文献速递重症综合管理与镇静镇痛

环丙泊酚用于ICU机械通气患者镇静的疗效与安全性:多中心、单盲、随机、非劣效性试验

Efficacy and Safety of Ciprofol Sedation in ICU Patients Undergoing Mechanical Ventilation: A Multicenter, Single-Blind, Randomized, Noninferiority Trial.
PubMed 文献 · Crit Care Med · 2023-06-05
一句话结论环丙泊酚在ICU机械通气患者6–24小时镇静中不劣于丙泊酚(FAS成功率97.7% vs 97.8%,非劣效界值8%),但苏醒时间更长(p=0.003)。

该多中心、单盲、随机、非劣效性试验在中国21个中心纳入135例18–80岁、气管插管行机械通气且预期需镇静6–24小时的ICU患者,按2:1随机接受环丙泊酚(n=90)或丙泊酚(n=45)镇静,目标RASS评分+1至-2,并持续静脉输注瑞芬太尼镇痛。主要终点镇静成功率在全分析集(FAS)中环丙泊酚组97.7% vs 丙泊酚组97.8%,符合方案集(PPS)中均为100%;组间差异双侧95%CI下限分别为-5.98%和-4.32%,均高于预设的8%非劣效界值。环丙泊酚组苏醒时间更长(p=0.003),其余次要终点无差异(均p>0.05);治疗中出现的不良事件(TEAE)或药物相关TEAE发生率组间无显著差异(均p>0.05)。结论认为环丙泊酚耐受性良好,在中国ICU机械通气6–24小时患者中镇静效果不劣于丙泊酚。

要点

  • 中国21中心、135例ICU机械通气患者(预期镇静6–24小时)2:1随机接受环丙泊酚(n=90)或丙泊酚(n=45),目标RASS +1至-2。
  • 主要终点镇静成功率:FAS中环丙泊酚97.7% vs 丙泊酚97.8%,PPS中两组均为100%;非劣效界值8%,组间差异双侧95%CI下限FAS -5.98%、PPS -4.32%,均确认非劣效。
  • 环丙泊酚组苏醒时间较丙泊酚组更长(p=0.003);其余次要终点组间无差异(均p>0.05)。
  • TEAE或药物相关TEAE发生率组间无显著差异(均p>0.05)。
  • 给药方案:环丙泊酚负荷量0.1 mg/kg、丙泊酚0.5 mg/kg,4分钟±30秒静脉输注;维持初始剂量环丙泊酚0.3 mg/kg/hr、丙泊酚1.5 mg/kg/hr;均持续静脉输注瑞芬太尼镇痛(负荷0.5-1 μg/kg,维持0.02-0.15 μg/kg/min)。

适用人群与场景

  • 18至80岁ICU患者,已行气管内插管并接受机械通气,预期需要镇静6–24小时。
  • 中国21个中心,2020年12月至2021年6月纳入。

诊断标准与关键阈值

  • 镇静目标范围:Richmond Agitation-Sedation Scale(RASS)+1至-2。
  • 非劣效界值设为8%。

处置流程与药物剂量

  • 环丙泊酚负荷量0.1 mg/kg,根据每位患者身体状况于4分钟±30秒内静脉输注;随后立即以初始维持剂量0.3 mg/kg/hr持续静脉输注,以达到目标RASS +1至-2。
  • 丙泊酚负荷量0.5 mg/kg,于4分钟±30秒内静脉输注;随后立即以初始维持剂量1.5 mg/kg/hr持续静脉输注,以达到目标RASS +1至-2。
  • 两组均持续静脉输注瑞芬太尼镇痛:负荷剂量0.5-1 μg/kg,维持剂量0.02-0.15 μg/kg/min。

研究设计与关键结果

  • 研究设计:多中心、单盲、随机、非劣效性试验,中国21个中心,2020年12月至2021年6月,纳入135例ICU机械通气患者,按2:1随机分为环丙泊酚组(n=90)和丙泊酚组(n=45),129例完成研究。
  • 主要终点镇静成功率:全分析集(FAS)中环丙泊酚组97.7% vs 丙泊酚组97.8%;符合方案集(PPS)中两组均为100%。
  • 非劣效性确认:组间差异双侧95%CI下限在FAS为-5.98%、在PPS为-4.32%,均高于预设非劣效界值8%。
  • 次要终点:环丙泊酚组苏醒时间更长(p=0.003);其余次要终点组间无差异(均p>0.05)。
  • 安全性:治疗中出现的不良事件(TEAE)或药物相关TEAE发生率组间无显著差异(均p>0.05)。

证据类型、等级与局限

  • 证据类型:多中心、单盲、随机、非劣效性试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于预期需要6–24小时镇静的ICU机械通气成人患者,环丙泊酚可按本试验方案(负荷0.1 mg/kg、维持0.3 mg/kg/hr起始)用于镇静,镇静成功率不劣于丙泊酚。
  • 使用环丙泊酚时需注意其苏醒时间较丙泊酚更长(p=0.003),在需要快速评估神经功能或计划拔管时需考虑这一差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To determine the effectiveness and safety of ciprofol for sedating patients in ICUs who required mechanical ventilation (MV).

DESIGN: A multicenter, single-blind, randomized, noninferiority trial.

SETTING: Twenty-one centers across China from December 2020 to June 2021.

PATIENTS: A total of 135 ICU patients 18 to 80 years old with endotracheal intubation and undergoing MV, who were expected to require sedation for 6-24 hours.

INTERVENTIONS: One hundred thirty-five ICU patients were randomly allocated into ciprofol ( n = 90) and propofol ( n = 45) groups in a 2:1 ratio. Ciprofol or propofol were IV infused at loading doses of 0.1 mg/kg or 0.5 mg/kg, respectively, over 4 minutes ± 30 seconds depending on the physical condition of each patient. Ciprofol or propofol were then immediately administered at an initial maintenance dose of 0.3 mg/kg/hr or 1.5 mg/kg/hr, to achieve the target sedation range of Richmond Agitation-Sedation Scale (+1 to -2). Besides, continuous IV remifentanil analgesia was administered (loading dose: 0.5-1 μg/kg, maintenance dose: 0.02-0.15 μg/kg/min).

MEASUREMENTS AND MAIN RESULTS: Of the 135 patients enrolled, 129 completed the study. The primary endpoint-sedation success rates of ciprofol and propofol groups were 97.7% versus 97.8% in the full analysis set (FAS) and were both 100% in per-protocol set (PPS). The noninferiority margin was set as 8% and confirmed with a lower limit of two-sided 95% CI for the inter-group difference of -5.98% and -4.32% in the FAS and PPS groups. Patients who received ciprofol had a longer recovery time ( p = 0.003), but there were no differences in the remaining secondary endpoints (all p > 0.05). The occurrence rates of treatment-emergent adverse events (TEAEs) or drug-related TEAEs were not significantly different between the groups (all p > 0.05).

CONCLUSIONS: Ciprofol was well tolerated, with a noninferior sedation profile to propofol in Chinese ICU patients undergoing MV for a period of 6-24 hours.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Liu Y, Peng Z, Liu S, et al. Efficacy and Safety of Ciprofol Sedation in ICU Patients Undergoing Mechanical Ventilation: A Multicenter, Single-Blind, Randomized, Noninferiority Trial. Crit Care Med. 2023. PMID: 37272947. doi:10.1097/CCM.0000000000005920

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。